ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "biologic response modifiers"

  • Abstract Number: 0595 • ACR Convergence 2024

    bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis

    Sélina HANNA ABDELMASSIH1, Tiphaine DUJARDIN2, Athan BAILLET1, Philippe GAUDIN1 and Xavier ROMAND1, 1Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France, 2Hôpital Reine Hortense, Aix-les-Bains, France

    Background/Purpose: During the last two decades we’ve witnessed the rising use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of psoriatic arthritis (PsA), leaving…
  • Abstract Number: 0665 • ACR Convergence 2024

    Belimumab Induces Early and Sustained Resolution of Lupus Thrombocytopenia and Lupus Arthritis

    Nicolai Leuchten1, Ioannis Parodis2, Ralph Brinks3 and Martin Aringer1, 1University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 2Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, 3University Witten/Herdecke, Witten, Germany

    Background/Purpose: Belimumab has well-established efficacy in improving overall SLE disease activity and in preventing flares and organ damage. In clinical routine, however, the primary goal…
  • Abstract Number: 1446 • ACR Convergence 2024

    Is the Remission Achieved with Asdas, Basdaı a Real Remission? Should Ultrasound Be Added to the Parameters?

    Emrah Koç1, Burak Okyar2, Sibel Bakırcı3, suade Özlem Badak2, Ali Nail Demir4, İsmail Uçar4, Gökhan Sargın5, Servet Yüce6 and Emine Duygu Ersözlü1, 1Adana City Training and Research Hospital, Adana, Turkey, 2Adana City Training and Research Hospital, Adana, 3Antalya training and research hospital, Antalya, Turkey, 4Mersin City Hospital, Mersin, Turkey, 5Aydin Adnan Menderes University, Aydın, Turkey, 6Şırnak Provincial Health Directorate Public Health Department, Şırnak, Turkey

    Background/Purpose: The study aimed to evaluate changes in enthesis areas in ankylosing spondylitis patients in remission for at least six months, using either NSAIDs or…
  • Abstract Number: 2268 • ACR Convergence 2024

    The Discontinuation and Effectiveness of Sequential Advanced Therapy in Rheumatoid Arthritis, a Real-World Data

    Mohammad Movahedi1, Angela Cesta2, Xiuying Li2, Bindee Kuriya3, Sibel Aydin4, Claire Bombardier5 and Pooneh Seyed-Akhavan6, and OBRI investigators, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2UHN, Toronto, ON, Canada, 3University of Toronto - Toronto, Toronto, ON, Canada, 4Ottawa Hospital Research Institute, Ottawa, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Sinai Health System, Toronto, ON, Canada

    Background/Purpose: Patients with rheumatoid arthritis (RA) who fail conventional synthetic treatment with disease modifying anti-rheumatic drugs (csDMARDs) are eligible for biological DMARDs (bDMARDs) or targeted…
  • Abstract Number: 2594 • ACR Convergence 2024

    A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways

    Saul Kivimae1, Sandip Mukherjee2, Phi Quach3, Rhoneil Pena4, Olga Zemska3, Michal Olszewski5, Jicai Huang3, Michael Labson6, Donald Walker1, Mekhala Maiti7, Chakrapani Tripathi8, Thomas Chang3, Suresh Adapala9, Damon Hamel3, Katherine Brendza3, Takahiro Miyazaki3 and Jonathan Zalevsky1, 1Nektar Therapeutics, San Francisco, CA, 2Nurix Therapeutics, San Francisco, 3Nektar Therapeutics, San Francisco, 4Sutro Biopharma, South San Francisco, 5Vaxcyte, San Francisco, 6Guardant Health, Palo Alto, 7Alumis, Inc, South San Francisco, 8Theragent Inc, Arcadia, CA, 9Inotiv, Rockville, MD

    Background/Purpose: Current standard of care chronic inflammatory disease therapies are designed to suppress inflammation and are not optimized for inflammation resolution and restoration of tissue…
  • Abstract Number: 0146 • ACR Convergence 2024

    Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions

    Bashar Tanous1, SRIKAR SAMA2, Nidaa Rasheed3 and Candice Reyes4, 1UCSF Fresno, Fresno, 2University of California San Francisco Fresno, Fresno, CA, 3UCSF Fresno, Fresno, CA, 4VACCHCS, Fresno, CA

    Background/Purpose: Biologic response modifiers (BRMs), also known as "biologics," have become essential tools in treating various chronic inflammatory conditions. However, the immunosuppression caused by these agents…
  • Abstract Number: 0381 • ACR Convergence 2024

    Two- and 3-Year Outcomes of the Childhood Arthritis and Rheumatology Research Alliance FROST Study of New-onset Systemic JIA Treatment

    Timothy Hahn1, George Tomlinson2, Yukiko Kimura3, Vincent Del Gaizo4, Carlos Valdes5 and Timothy Beukelman6, and for the CARRA FROST Investigators, 1Penn State Childrens Hospital, Hershey, PA, 2University of Toronto, Toronto, ON, Canada, 3Hackensack Meridian School of Medicine, New York, NY, 4Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, 5Genentech, Davie, FL, 6University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The FiRst Line Options for sJIA Treatment (FROST) trial was a prospective observational study designed to compare the effectiveness of 4 Childhood Arthritis and…
  • Abstract Number: 0408 • ACR Convergence 2024

    Analysis of Protein Biomarkers for the Prediction of IL-1 Inhibitor Treatment Response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study

    Michael Matt1, Mariana Correia Marques2, Sabrina Fuehner3, Lexi Auld1, George Tomlinson4, Michael Ombrello5, Yukiko Kimura6, Christoph Kessel7 and grant schulert1, and the CARRA FROST Investigators, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2National Institutes of Health, Bethesda, MD, 3Universitaetsklinikum Muenster, Muenster, Germany, 4University of Toronto, Toronto, ON, Canada, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 6Hackensack Meridian School of Medicine, New York, NY, 7University Hospital Muenster, Muenster, Germany

    Background/Purpose: IL-1 inhibitors are both widely used and highly effective as first-line therapy for children with systemic juvenile idiopathic arthritis (sJIA); however, the mechanisms underlying…
  • Abstract Number: 0410 • ACR Convergence 2024

    Efficacy of Modified Dosing/interval Timing of Adalimumab in Patients Affected by Chronic Non Infectious Uveitis: A Retrospective Monocentric Study

    Melissa Lerman1, Devlin Eckardt1 and Sabino Germinario2, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Università degli studi di Milano, Milan, Italy

    Background/Purpose: Non-infectious uveitis (NIU), inflammation of the eye, can occur in isolation, as in idiopathic uveitis (29% of all pediatric diagnosis), but may also be…
  • Abstract Number: 0505 • ACR Convergence 2024

    UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi

    George Karpouzas1, Lixia Zhang2, Mark Zielinski2, Brian Cheng2 and Sherry Guardiano3, 1Harbor-UCLA Medical Center, Torrance, CA, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corporation, Keene, NH

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
  • Abstract Number: 0572 • ACR Convergence 2024

    Synergistic Impact of the Non-radiographic Axial Spondyloarthritis Subtype and Female Sex on First-Line Biologic Discontinuation : A Study of Interaction Effects

    Patricia Remalante-Rayco1, Emmanuel Baja2, Zeynep Baskurt3, Tina Chim4, Robert Inman5, Leonila Dans6 and Nigil Haroon7, 1Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 2Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, Manila, Philippines, 3Department of Biostatistics, University Health Network, Toronto, Canada, 4Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, 5University Health Network, Toronto, ON, Canada, 6Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines, 7Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Recent evidence suggests lower response rates to tumor necrosis factor inhibitors (TNFi) among women with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is a paucity…
  • Abstract Number: 0580 • ACR Convergence 2024

    Cellular Immune Activation Signatures at Baseline Predict Response to TNF Inhibitors in Axial Spondyloarthritis

    Ayantika Talukdar1, Neke Ibeh2, Rohan Machhar2, Mansi Aparnathi3, Sareh Keshavarazi4, Archita Srinath5, Akihiro Nakamura6, Robert Inman7, Proton Rahman8, Igor Jurisica9 and Nigil Haroon10, 1Krembil Research Institute, UHN, Toronto, ON, Canada, 2UHN, Toronto, Canada, 3University Health Network, Toronto, Canada, 4UHN, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Queen's Univesity, Kingston, ON, Canada, 7University Health Network, Toronto, ON, Canada, 8Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, 9Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, 10Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) substantially improve symptoms in Ankylosing Spondylitis (AS), although 40% patients are unresponsive. Identifying biomarkers predictive of TNFi treatment response…
  • Abstract Number: 0382 • ACR Convergence 2023

    Heterogeneity Within a “difficult to Treat” Rheumatoid Arthritis Patients Cohort: 36% May Have a More Benign Course and Have Distinct Characteristics at bDMARD or tsDMARD Initiation

    Irini Flouri1, Antonios Bertsias2, Argyro Repa2, Nestor Avgoustidis2, Eleni Kalogiannaki2, Sofia Pitsigavdaki3, George Bertsias4 and Prodromos Sidiropoulos4, 1University of Crete Medical School, Heraklion, Greece, 2Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, 3Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, 4Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece

    Background/Purpose: Early detection of difficult to treat (D2T) RA patients as well as better characterization of their long-term course represent unresolved issues. Herein we aimed…
  • Abstract Number: 0542 • ACR Convergence 2023

    Two-Year Treatment Adherence and Clinical Response to Secukinumab Compared to TNF Inhibitors in Axial and Peripheral Spondyloarthritis Patients: A Single-Center Prospective Observational Study

    Irini Flouri1, Argyro Repa2, Nestor Avgoustidis2, Sofia Pitsigavdaki3, Katerina Pateromichelaki2, Maria Terizaki2, George Bertsias4 and Prodromos Sidiropoulos4, 1University of Crete Medical School, Heraklion, Greece, 2Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, 3Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, 4Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece

    Background/Purpose: Anti-IL17 agent secukinumab (SEC) has been proven effective and is widely used in the treatment of spondyloarthritis (SpA) patients alternatively to tumor necrosis factor…
  • Abstract Number: 0831 • ACR Convergence 2023

    Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study

    Sarah Ringold1, George Tomlinson2, Laura Schanberg3, vincent del gaizo4, Katherine Murphy5, Brian Feldman6, Mei-Sing Ong7, Marc Natter8, Yukiko Kimura9 and For The CARRA Registry Investgators4, 1Seattle Children's Hospital, Seattle, WA, 2University of Toronto, Toronto, ON, Canada, 3Duke University School of Medicine, Durham, NC, 4CARRA, Inc, Washington, DC, 5Non-clinical, New Orleans, LA, 6The Hospital for Sick Children, Toronto, ON, Canada, 7Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, 8Harvard Medical School, Boston, MA, 9Hackensack Meridian School of Medicine, New York, NY

    Background/Purpose: The STOP-JIA study was designed to compare the effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus Treatment Plans (CTPs) for untreated…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology